Keystone Financial Planning Inc. reduced its stake in Sanofi (NYSE:SNY) by 1.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 41,277 shares of the company’s stock after selling 610 shares during the period. Keystone Financial Planning Inc.’s holdings in Sanofi were worth $1,978,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Pennsylvania Trust Co raised its position in Sanofi by 0.4% in the second quarter. Pennsylvania Trust Co now owns 8,314 shares of the company’s stock valued at $402,000 after buying an additional 37 shares in the last quarter. Rehmann Capital Advisory Group raised its position in Sanofi by 0.7% in the second quarter. Rehmann Capital Advisory Group now owns 7,235 shares of the company’s stock valued at $347,000 after buying an additional 47 shares in the last quarter. Weik Investment Services Inc. raised its position in Sanofi by 0.9% in the first quarter. Weik Investment Services Inc. now owns 5,895 shares of the company’s stock valued at $267,000 after buying an additional 50 shares in the last quarter. Financial Advisors Network Inc. raised its position in Sanofi by 1.0% in the first quarter. Financial Advisors Network Inc. now owns 8,282 shares of the company’s stock valued at $409,000 after buying an additional 84 shares in the last quarter. Finally, First City Capital Management Inc. raised its position in Sanofi by 0.3% in the first quarter. First City Capital Management Inc. now owns 38,289 shares of the company’s stock valued at $1,733,000 after buying an additional 100 shares in the last quarter. Institutional investors own 9.96% of the company’s stock.

Sanofi (NYSE:SNY) opened at 47.55 on Friday. The firm’s 50 day moving average price is $47.99 and its 200 day moving average price is $46.11. Sanofi has a 12 month low of $36.81 and a 12 month high of $50.24. The stock has a market cap of $119.42 billion, a price-to-earnings ratio of 11.23 and a beta of 0.88.

Sanofi (NYSE:SNY) last issued its quarterly earnings results on Monday, July 31st. The company reported $0.74 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.74. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The company had revenue of $8.66 billion during the quarter, compared to analysts’ expectations of $8.71 billion. The business’s quarterly revenue was down 2.3% compared to the same quarter last year. On average, equities research analysts predict that Sanofi will post $3.26 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Keystone Financial Planning Inc. Sells 610 Shares of Sanofi (NYSE:SNY)” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://theolympiareport.com/2017/08/12/keystone-financial-planning-inc-sells-610-shares-of-sanofi-nysesny.html.

Several research analysts recently commented on the company. BidaskClub lowered Sanofi from a “buy” rating to a “hold” rating in a research report on Friday, June 9th. Argus lifted their price target on Sanofi from $50.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday, June 9th. Zacks Investment Research upgraded Sanofi from a “hold” rating to a “buy” rating and set a $55.00 target price for the company in a research report on Friday, June 2nd. Berenberg Bank lowered Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, May 11th. Finally, TheStreet upgraded Sanofi from a “c+” rating to a “b-” rating in a research report on Monday, April 24th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $63.75.

About Sanofi

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with Analyst Ratings Network's FREE daily email newsletter.